Trial Profile
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Major depressive disorder
- Focus Proof of concept; Therapeutic Use
- Sponsors Allergan
- 11 Oct 2019 Results assessing the efficacy, safety, and duration of effect of a single-treatment session of onabotA compared to placebo for the treatment of major depressive disorder in adult females published in the International Clinical Psychopharmacology
- 05 Apr 2017 Primary endpoint of change from baseline in the clinic 10-item montgomery-asberg depression rating scale (MADRS) total score for Botulinum toxin A 30 U vs. placebo has been met, according to results published in an Allergan media release.
- 05 Apr 2017 Top-line results published in an Allergan media release